Skip to content

Impact of Persistent Microvascular Obstruction by Cardiac Magnetic Resonance on Prognosis for ST-segment Elevation Myocardial Infarction

Prognostic Role of Persistent Microvascular Obstruction by Cardiac Magnetic Resonance for ST-segment Elevation Myocardial Infarction

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06759532
Acronym
IMCOME
Enrollment
344
Registered
2025-01-06
Start date
2017-04-01
Completion date
2024-10-20
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Elevation (STEMI) Myocardial Infarction

Keywords

Microvascular occlusion;, ST-segment elevation myocardial infarction, Prognosis

Brief summary

The aims of the study were to evaluate the predictive value of persistent microvascular obstruction (MVO) by cardiac magnetic resonance for main adverse cardiac events in ST-segment elevation myocardial infarction patients. MVO in the acute phase of myocardial infarction has been considered to be strong predictor of a poor prognosis. We plan to explore the relationship between persistent MVO and the long-term prognosis of patients with STEMI. We made hypothesis that patients with persistent MVO have a poor prognosis.

Interventions

None listed

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* ST-segment elevation myocardial infarction undewent primary percutaneous coronary intervention

Exclusion criteria

* contraindications for cardiac magnetic resonance * severe heart failure * previous myocardial infarction.

Design outcomes

Primary

MeasureTime frameDescription
Main aderverse cardiac events5 years after myocardiac infarctionComposite endpoint of all-cause death, readmission due to heart failure, recurrent myocardial infarction, and unexpected vascularization.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026